Treatment Options for People With Prostate Cancer From 5 Experts
Released: November 22, 2023
Share
Tanya B. Dorff, MD
Professor of Medicine
Vice Chair for Clinical Affairs
Department of Medical Oncology
City of Hope National Medical Center
Duarte, California
Rana R. McKay, MD
Associate Professor of Medical Oncology and Urology
Associate Director, Clinical Sciences
Co-Lead, Genitourinary Malignancies Program
Moores Cancer Center
University of California San Diego
La Jolla, California
Alicia Morgans, MD, MPH
Associate Professor
Dana-Farber Cancer Institute Boston, MassachusettsMichael Schweizer, MD
Associate Professor
Clinical Research Division
Department of Medical Oncology
University of Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington
David VanderWeele, MD, PhD
Associate Professor
Department of Hematology/Oncology
Northwestern University
Attending Physician
Department of Hematology/Oncology
Jesse Brown VA Medical Center
Chicago, Illinois
Provided by Clinical Care Options, LLC in partnership with ZERO Cancer
AstraZeneca
Bayer HealthCare Pharmaceuticals Inc.
Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC.
Lilly
Merck Sharp & Dohme Corp.
Novartis Pharmaceuticals Corporation
ZERO Prostate Cancer
Primary Author
Tanya B. Dorff, MD
Professor of Medicine
Vice Chair for Clinical Affairs
Department of Medical Oncology
City of Hope National Medical Center
Duarte, California
Tanya B. Dorff, MD: consultant/advisor/speaker: Astellas, AstraZeneca, Bayer, Exelixis, Janssen, Sanofi, SeaGen.
Rana R. McKay, MD
Associate Professor of Medical Oncology and Urology
Associate Director, Clinical Sciences
Co-Lead, Genitourinary Malignancies Program
Moores Cancer Center
University of California San Diego
La Jolla, California
Rana R. McKay, MD: consultant/advisor/speaker: AstraZeneca, Aveo, Bristol-Myers Squibb, Bayer, Calithera, Caris, Dendreon, Eisaix, Exelixis, Johnson & Johnson, Lilly, Myovant, Merck, Novartis, Pfizer, Sanofi, Seagen, Sorrento, Telix, Tempus; research funding (paid to institution): Artera, Bayer, BMS, Exelixis, AstraZeneca, Oncternal, Tempus.
Alicia Morgans, MD, MPH
Associate Professor
Dana-Farber Cancer Institute Boston, MassachusettsAlicia K. Morgans, MD, MPH: consultant/advisor/speaker: AAA, Astellas, AstraZeneca, Bayer, Dendreon, Foundation Medicine, Exelixis, Janssen, Lantheus, Myovant, Myriad, Novartis, Pfizer, Sanofi, SeaGen, Telix.
Michael Schweizer, MD
Associate Professor
Clinical Research Division
Department of Medical Oncology
University of Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington
Michael Schweizer, MD: consultant/advisor/speaker: AstraZeneca, PharmaIn, Sanofi; researcher (paid to institution): AstraZeneca, Ambrx, Bristol Myers Squibb, Epigenetix, Hoffman-La Roche, Immunomedics, Incyte, Janssen, Merck, Pfizer, SignalOne Bio, Tmunity, Xencoer, Zenith Epigenetics.
David VanderWeele, MD, PhD
Associate Professor
Department of Hematology/Oncology
Northwestern University
Attending Physician
Department of Hematology/Oncology
Jesse Brown VA Medical Center
Chicago, Illinois
David VanderWeele, MD, PhD: consultant/advisor/speaker: Astellas, Bayer, Exelixis, Janssen.